SANGAMO THERAPEUTICS INC (SGMO) Stock Overview
NASDAQ:SGMO - US8006771062 - Common Stock
SGMO Key Statistics, Chart & Performance
The current stock price of SGMO is 0.534 USD. In the past month the price increased by 0.75%. In the past year, price decreased by -26.14%.
SGMO Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 20.01 | 374.26B | ||
| AMGN | AMGEN INC | 13.01 | 152.81B | ||
| GILD | GILEAD SCIENCES INC | 14.6 | 140.20B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.41 | 101.69B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.35 | 59.76B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 58.65B | ||
| ARGX | ARGENX SE - ADR | 77.89 | 44.19B | ||
| ONC | BEONE MEDICINES LTD-ADR | 6.78 | 39.97B | ||
| INSM | INSMED INC | N/A | 30.33B | ||
| BNTX | BIONTECH SE-ADR | N/A | 24.14B | ||
| NTRA | NATERA INC | N/A | 22.99B | ||
| BIIB | BIOGEN INC | 8.85 | 20.76B |
Related stock screener links
About SGMO
Company Profile
Sangamo Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the research and development of zinc finger proteins. The company is headquartered in Richmond California, California and currently employs 183 full-time employees. The company went IPO on 2000-04-06. The Company’s zinc finger (ZF) epigenetic regulators are ideally suited to potentially address neurological disorders and its capsid engineering platform has demonstrated the ability to expand delivery beyond available intrathecal delivery capsids, including in the central nervous system (CNS), in preclinical studies. Zinc finger technologies are derived from naturally occurring human proteins. They are composed of a DNA-binding domain, which binds with precision to any sequence of DNA, and various functional domains (such as nucleases and transcription factors) based on therapeutic needs. Its pipeline includes Chronic Neuropathic Pain - ST-503 and Isaralgagene civaparvovec (ST-920). ST-503 is an investigational epigenetic regulator for the treatment of intractable pain due to iSFN, a type of chronic neuropathic pain. ST-920 is a wholly owned gene therapy product candidate for the treatment of Fabry disease.
Company Info
SANGAMO THERAPEUTICS INC
501 Canal Blvd.
Richmond California CALIFORNIA 94005 US
CEO: Alexander D. Macrae
Employees: 183
Phone: 15109706000
SANGAMO THERAPEUTICS INC / SGMO FAQ
What is the stock price of SANGAMO THERAPEUTICS INC today?
The current stock price of SGMO is 0.534 USD. The price decreased by -1% in the last trading session.
What is the ticker symbol for SANGAMO THERAPEUTICS INC stock?
The exchange symbol of SANGAMO THERAPEUTICS INC is SGMO and it is listed on the Nasdaq exchange.
On which exchange is SGMO stock listed?
SGMO stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for SANGAMO THERAPEUTICS INC stock?
12 analysts have analysed SGMO and the average price target is 4.18 USD. This implies a price increase of 683.15% is expected in the next year compared to the current price of 0.534. Check the SANGAMO THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is SANGAMO THERAPEUTICS INC worth?
SANGAMO THERAPEUTICS INC (SGMO) has a market capitalization of 161.11M USD. This makes SGMO a Micro Cap stock.
How many employees does SANGAMO THERAPEUTICS INC have?
SANGAMO THERAPEUTICS INC (SGMO) currently has 183 employees.
What are the support and resistance levels for SANGAMO THERAPEUTICS INC (SGMO) stock?
SANGAMO THERAPEUTICS INC (SGMO) has a support level at 0.51 and a resistance level at 0.59. Check the full technical report for a detailed analysis of SGMO support and resistance levels.
Is SANGAMO THERAPEUTICS INC (SGMO) expected to grow?
The Revenue of SANGAMO THERAPEUTICS INC (SGMO) is expected to grow by 13.56% in the next year. Check the estimates tab for more information on the SGMO EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy SANGAMO THERAPEUTICS INC (SGMO) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of SGMO, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of SGMO, evaluating the profitability, health, valuation and growth aspects
- SANGAMO THERAPEUTICS INC (SGMO) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- SANGAMO THERAPEUTICS INC (SGMO) Sales and EPS estimates to see what analysts future expectations are.
- SANGAMO THERAPEUTICS INC (SGMO) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- SANGAMO THERAPEUTICS INC (SGMO) Insider and Institutional Ownership to learn about the owners and their transactions.
- SANGAMO THERAPEUTICS INC (SGMO) Stock Chart to make your own analysis
- SANGAMO THERAPEUTICS INC (SGMO) Latest news and press-releases to stay up to date.
Does SANGAMO THERAPEUTICS INC (SGMO) stock pay dividends?
SGMO does not pay a dividend.
When does SANGAMO THERAPEUTICS INC (SGMO) report earnings?
SANGAMO THERAPEUTICS INC (SGMO) will report earnings on 2025-11-10, after the market close.
What is the Price/Earnings (PE) ratio of SANGAMO THERAPEUTICS INC (SGMO)?
SANGAMO THERAPEUTICS INC (SGMO) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.29).
What is the Short Interest ratio of SANGAMO THERAPEUTICS INC (SGMO) stock?
The outstanding short interest for SANGAMO THERAPEUTICS INC (SGMO) is 5.41% of its float. Check the ownership tab for more information on the SGMO short interest.
SGMO Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to SGMO. When comparing the yearly performance of all stocks, SGMO is a bad performer in the overall market: 85.59% of all stocks are doing better.
SGMO Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to SGMO. While SGMO seems to be doing ok healthwise, there are quite some concerns on its profitability.
SGMO Financial Highlights
Over the last trailing twelve months SGMO reported a non-GAAP Earnings per Share(EPS) of -0.29. The EPS increased by 78.99% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -66.21% | ||
| ROE | -329.53% | ||
| Debt/Equity | 0 |
SGMO Forecast & Estimates
12 analysts have analysed SGMO and the average price target is 4.18 USD. This implies a price increase of 683.15% is expected in the next year compared to the current price of 0.534.
For the next year, analysts expect an EPS growth of 41.91% and a revenue growth 13.56% for SGMO